1513.HK Livzon Pharmaceutical Misses Q1 2026 Earnings Targets

Livzon Pharmaceutical Group Inc. (1513.HK) reported disappointing earnings results on April 23, 2026. The Hong Kong-listed pharmaceutical company missed both earnings and revenue targets. Earnings per share came in at $0.7390, falling short of the $0.8180 estimate by 9.66%. Revenue reached $3.26 billion, missing the $3.60 billion forecast by 9.50%. These misses signal operational challenges for the specialty drug manufacturer. The stock currently trades at HK$28.26 with a market cap of $30.67 billion. Meyka AI rates 1513.HK with a grade of B+, suggesting cautious optimism despite the earnings disappointment.

Earnings Miss Signals Operational Pressure

Livzon Pharmaceutical’s first quarter results fell short of analyst expectations across both key metrics. The company reported EPS of $0.7390 versus the estimated $0.8180, representing a 9.66% miss. Revenue came in at $3.26 billion against the $3.60 billion forecast, a 9.50% shortfall. These dual misses suggest the company faced headwinds in production, sales, or market demand during the quarter.

Revenue Decline Reflects Market Challenges

The $340 million revenue shortfall indicates Livzon struggled to meet market demand or faced pricing pressures. As a specialty and generic drug manufacturer, the company operates in competitive markets. The miss suggests either lower-than-expected sales volumes or reduced pricing power. This is particularly concerning given the company’s focus on high-margin pharmaceutical products and diagnostic reagents.

Earnings Per Share Deterioration

The EPS miss of $0.0790 per share points to profitability challenges beyond just revenue. This could reflect higher operating costs, increased R&D expenses, or margin compression. With a net profit margin of 16.86% trailing twelve months, the company maintains reasonable profitability. However, the quarterly miss suggests recent operational efficiency declined from historical levels.

Stock Performance and Market Reaction

Livzon’s stock showed resilience following the earnings miss, trading up 0.50% on the day. The stock closed at HK$28.26, near its 50-day moving average of HK$28.45. This modest gain suggests the market had partially priced in the disappointing results. The stock remains well below its 52-week high of HK$41.85, down approximately 32.5% from peak levels.

Technical Position Remains Weak

The stock’s technical indicators show mixed signals. The RSI stands at 45.82, indicating neither overbought nor oversold conditions. The MACD histogram is slightly negative at -0.02, suggesting weakening momentum. The Stochastic oscillator at 36.46 indicates potential oversold conditions, which may support a bounce. However, the ADX at 17.33 shows no clear trend direction.

Valuation Metrics Offer Some Support

The stock trades at a PE ratio of 10.75, below the historical average. The price-to-sales ratio of 2.23 appears reasonable for a pharmaceutical company. The dividend yield of 4.27% provides income support for long-term holders. These valuation metrics suggest the stock may offer value at current levels despite the earnings miss.

Financial Health and Operational Metrics

Despite the earnings miss, Livzon maintains solid financial fundamentals. The company carries a debt-to-equity ratio of 0.28, indicating conservative leverage. Cash per share stands at HK$12.30, providing financial flexibility. The current ratio of 2.23 shows strong short-term liquidity. These metrics suggest the company can weather near-term challenges.

Cash Flow Generation Remains Positive

Operating cash flow per share reached HK$3.59 trailing twelve months, while free cash flow per share was HK$2.94. The company generated positive free cash flow despite the quarterly miss. This cash generation supports the dividend, which yields 4.27% annually. The company paid HK$1.04 per share in dividends, demonstrating commitment to shareholders.

Return on Equity and Asset Efficiency

Return on equity stands at 14.50% trailing twelve months, indicating reasonable profitability. Return on assets is 8.41%, showing efficient asset utilization. The company’s inventory turnover of 2.64 times annually is typical for pharmaceutical manufacturers. Days sales outstanding of 106.6 days reflects normal pharmaceutical industry payment terms.

Forward Outlook and Investment Implications

The earnings miss raises questions about Livzon’s near-term growth trajectory. However, the company’s long-term fundamentals remain intact. Meyka AI rates 1513.HK with a B+ grade, reflecting mixed signals. The rating incorporates strong ROA and DCF scores balanced against debt concerns. Analysts expect the stock to reach HK$35.73 within one year, implying 26.5% upside from current levels.

Pharmaceutical Market Dynamics

Livzon operates in China’s pharmaceutical sector, which faces regulatory pressures and pricing controls. The company’s specialty drug portfolio and diagnostic reagent business provide diversification. Recent inventory reduction of 21.8% year-over-year suggests management is optimizing working capital. This operational discipline may support future profitability improvements.

Dividend Sustainability and Shareholder Returns

The payout ratio of 82.5% is elevated but manageable given cash flow generation. The company’s commitment to dividends despite the earnings miss demonstrates confidence in recovery. Management’s willingness to maintain distributions suggests they view current challenges as temporary. Investors seeking income may find value in the 4.27% yield at current prices.

Final Thoughts

Livzon Pharmaceutical missed earnings expectations on both EPS and revenue, reflecting near-term operational challenges. However, the company maintains strong financial fundamentals with a low 0.28 debt-to-equity ratio, solid cash position, and 4.27% dividend yield. The modest stock reaction suggests the market anticipated weak results. With a B+ grade and 26.5% upside potential from analyst targets, the stock may appeal to patient investors. Management’s maintained dividend signals confidence in recovery, though investors should monitor upcoming quarters for operational improvement signs.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.